[HTML][HTML] Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials
DK Nambiar, D Mishra, RP Singh - Oncology research, 2023 - ncbi.nlm.nih.gov
Ionizing radiation is frequently used to treat solid tumors, as it causes DNA damage and kill
cancer cells. However, damaged DNA is repaired involving poly-(ADP-ribose) polymerase-1 …
cancer cells. However, damaged DNA is repaired involving poly-(ADP-ribose) polymerase-1 …
Quiescent cancer cells—a potential therapeutic target to overcome tumor resistance and relapse
E Lindell, L Zhong, X Zhang - International Journal of Molecular Sciences, 2023 - mdpi.com
Quiescent cancer cells (QCCs) are nonproliferating cells arrested in the G0 phase,
characterized by ki67low and p27high. QCCs avoid most chemotherapies, and some …
characterized by ki67low and p27high. QCCs avoid most chemotherapies, and some …
Discovery of KB-0742, a potent, selective, orally bioavailable small molecule inhibitor of CDK9 for MYC-dependent cancers
DB Freeman, TD Hopkins, PJ Mikochik… - Journal of Medicinal …, 2023 - ACS Publications
Transcriptional deregulation is a hallmark of many cancers and is exemplified by genomic
amplifications of the MYC family of oncogenes, which occur in at least 20% of all solid …
amplifications of the MYC family of oncogenes, which occur in at least 20% of all solid …
Imidazopyridine-based kinase inhibitors as potential anticancer agents: A review
F Peytam, Z Emamgholipour, A Mousavi, M Moradi… - Bioorganic …, 2023 - Elsevier
Considering the fundamental role of protein kinases in the mechanism of protein
phosphorylation in critical cellular processes, their dysregulation, especially in cancers, has …
phosphorylation in critical cellular processes, their dysregulation, especially in cancers, has …
CircNCOR1 regulates breast cancer radiotherapy efficacy by regulating CDK2 via hsa-miR-638 binding
ZY He, RG Zhuo, SP Yang, P Zhou, JY Xu, J Zhou… - Cellular …, 2023 - Elsevier
Background Despite aggressive local and regional therapy, triple-negative breast cancer
(TNBC) is characterized by an increased risk of locoregional recurrence. RNA-sequencing …
(TNBC) is characterized by an increased risk of locoregional recurrence. RNA-sequencing …
Mechanism of CDK4/6 inhibitor resistance in hormone receptor-positive breast cancer and alternative treatment strategies
CM Chang, HYP Lam - Anticancer Research, 2023 - ar.iiarjournals.org
Breast cancer (BC) is a common malignancy in women, with hormone receptor (HR)-positive
subtype responsible for approximately 70% of cases. Currently, patients with metastatic HR …
subtype responsible for approximately 70% of cases. Currently, patients with metastatic HR …
A Systematic Review of Stem Cell Differentiation into Keratinocytes for Regenerative Applications
To improve wound healing or treatment of other skin diseases, and provide model cells for
skin biology studies, in vitro differentiation of stem cells into keratinocyte-like cells (KLCs) is …
skin biology studies, in vitro differentiation of stem cells into keratinocyte-like cells (KLCs) is …
Design, synthesis, antineoplastic activity of new pyrazolo [3, 4-d] pyrimidine derivatives as dual CDK2/GSK3β kinase inhibitors; molecular docking study, and ADME …
In the current study, novel pyrazolo [3, 4-d] pyrimidine derivatives 5a–h were designed and
synthesized as targeted anti-cancer agents through dual CDK2/GSK-3β inhibition. The …
synthesized as targeted anti-cancer agents through dual CDK2/GSK-3β inhibition. The …
Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions
R Gerosa, R De Sanctis, F Jacobs, C Benvenuti… - Critical Reviews in …, 2024 - Elsevier
Aberrant cyclin-dependent kinase 2 (CDK2) activation has been identified as a main
resistance mechanism to CDK4/6 inhibition in hormone-positive (HR+) breast cancer …
resistance mechanism to CDK4/6 inhibition in hormone-positive (HR+) breast cancer …
[HTML][HTML] Anti-hepatocellular carcinoma activity of the cyclin-dependent kinase inhibitor AT7519
K Karaś, I Karwaciak, K Chałaśkiewicz… - Biomedicine & …, 2023 - Elsevier
Hepatocellular carcinoma (HCC) is one of the most common cancerous tumors and one of
the leading causes of death among cancer-related disorders. Chemotherapy is ineffective in …
the leading causes of death among cancer-related disorders. Chemotherapy is ineffective in …